ReviewDisease markers2015
Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability.
Review in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Podcast Episode 1: A Pragmatic Overview of Heart Failure in Patients with Diabetes for Endocrinologists, Primary Care Physicians and Noncardiologist Clinicians.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Diabetic kidney disease, biomarkers, and finerenone.Diabetes, obesity & metabolism · 2026Review
- Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis.BMC nephrology · 2025Observational
- Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome.Frontiers in cardiovascular medicine · 2025Review
- Evaluating the impact of chronic kidney disease and the triglyceride-glucose index on cardiovascular disease: mediation analysis in the NHANES.BMC public health · 2024Article
- Acute Kidney Injury and High-Sensitivity Cardiac Troponin T Levels in the Emergency Department.JAMA network open · 2024Article
- Thrombospondin-1 in Chronic Kidney Disease Driven Cardiac Dysfunction: More Than Just a Biomarker?JACC. Basic to translational science · 2024Article
- Chronic Kidney Disease Associated with Ischemic Heart Disease: To What Extent Do Biomarkers Help?Life (Basel, Switzerland) · 2023Review
- Review
- Emerging Biomarkers for Early Detection of Chronic Kidney Disease.Journal of personalized medicine · 2022Review
- Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease.Clinical and translational science · 2022Article
- Oxidative Stress in Non-Dialysis-Dependent Chronic Kidney Disease Patients.International journal of environmental research and public health · 2021Article
- Calciprotein Particles: Balancing Mineral Homeostasis and Vascular Pathology.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Cardiorenal Fat: A Cardiovascular Risk Factor With Implications in Chronic Kidney Disease.Frontiers in medicine · 2021 · on this mapReview
- High-Sensitivity C-Reactive Protein Elevation Is Independently Associated with Subclinical Renal Impairment in the Middle-Aged and Elderly Population-A Community-Based Study in Northern Taiwan.International journal of environmental research and public health · 2020Article
- Review
- Epicardial Adipose Tissue, Adiponectin and Leptin: A Potential Source of Cardiovascular Risk in Chronic Kidney Disease.International journal of molecular sciences · 2020Review
- The rs1126616 Single Nucleotide Polymorphism of the Osteopontin Gene Is Independently Associated with Cardiovascular Events in a Chronic Kidney Disease Cohort.Journal of clinical medicine · 2019Article
- Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality.Mediators of inflammation · 2019Article
- 0/1-Hour Triage Algorithm for Myocardial Infarction in Patients With Renal Dysfunction.Circulation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high incidence of cardiovascular events in chronic kidney disease (CKD) warrants an accurate evaluation of risk aimed at reducing the burden of disease and its consequences. The use of biomarkers to identify patients at high risk has been in use in the general population for several decades and has received mixed reactions in the medical community. Some practitioners have become staunch supporters and users while others doubt the utility of biomarkers and rarely measure them. In CKD patients numerous markers similar to those used in the general population and others more specific to the uremic population have emerged; however their utility for routine clinical application remains to be fully elucidated. The reproducibility and standardization of the serum assays are serious limitations to the broad implementation of these tests. The lack of focused research and validation in randomized trials rather than ad hoc measurement of multiple serum markers in observational studies is also cause for concern related to the clinical applicability of these markers. We review the current literature on biomarkers that may have a relevant role in field of nephrology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.